KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Payables (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Payables for 15 consecutive years, with $107.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 41.19% to $107.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.8 million, a 41.19% increase, with the full-year FY2025 number at $107.8 million, up 41.19% from a year prior.
  • Payables was $107.8 million for Q4 2025 at Supernus Pharmaceuticals, up from $76.9 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $498.3 million in Q4 2022 to a low of $70.1 million in Q1 2021.
  • A 5-year average of $145.7 million and a median of $81.1 million in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: surged 2143.89% in 2021, then crashed 84.03% in 2023.
  • Supernus Pharmaceuticals' Payables stood at $117.7 million in 2021, then soared by 323.43% to $498.3 million in 2022, then plummeted by 84.03% to $79.6 million in 2023, then dropped by 4.04% to $76.4 million in 2024, then skyrocketed by 41.19% to $107.8 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Payables are $107.8 million (Q4 2025), $76.9 million (Q1 2025), and $76.4 million (Q4 2024).